GeneWerk’s journey began long before the company was officially founded in 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt and Dr. Annette Deichmann as an academic spin-off of the German Cancer Research Center (DKFZ).
GeneWerk GmbH was founded in July 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt and Dr. Annette Deichmann.
GeneWerk’s founding team was involved in the safety assessment of Glybera, the first approved gene therapy drug in a western country.
Gene therapy safety testing fee-for-service initiated at the German Cancer Research Center (DKFZ), Heidelberg, Germany.
GeneWerk’s founding team was involved in the identification of retroviral integration-related serious adverse events (SAEs) in X-linked severe combined immunodeficiency (X-SCID) patients.
LAM-PCR, the then gold standard for vector integration site analysis developed by Dr. Manfred Schmidt, was used in the first Europe-wide gene marking trial in Chronic Myelogenous Leukemia (CML) patients.
Want to get in touch?
Consult with our experts about solutions to your biosafety challenges.